Sun Pharmaceutical Industries Limited — Important, 28-10-2024: Financial Result Updates

Sun Pharmaceutical Industries Limited reported a robust performance for Q2FY25, with gross sales at ₹132,642 million, up 10.5% year-on-year. Net profit surged to ₹30,402 million, a 28% increase. Key growth drivers included an 11% rise in India formulations sales and a 20.3% increase in US formulations. The company's R&D investments were ₹7,929 million, reflecting its commitment to innovation. Additionally, Sun Pharma's market share in the Indian pharmaceutical sector has increased, reinforcing its leadership position.